The study is ongoing at clinics in the US and will assess the safety, tolerability and pharmacokinetics of Factor IXFc (FIXFc) in this patient population.
This FIXFc compound, which preclinical studies have shown to have an extended half-life, could enable effective treatment with less frequent injections for both prophylaxis and on-demand therapy in hemophilia B.
Martin Nicklasson, CEO of Biovitrum, said: “We are excited about developing FIXFc together with Syntonix since hemophilia is a prioritized therapeutic and business area within Biovitrum. In addition, we are developing a recombinant Factor VIIIFc hemophilia product with Syntonix.”